201 related articles for article (PubMed ID: 17678435)
1. Novel interaction between HPV E6 and BARD1 (BRCA1-associated ring domain 1) and its biologic roles.
Yim EK; Lee KH; Myeong J; Tong SY; Um SJ; Park JS
DNA Cell Biol; 2007 Oct; 26(10):753-61. PubMed ID: 17678435
[TBL] [Abstract][Full Text] [Related]
2. Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6.
Matsumoto Y; Nakagawa S; Yano T; Takizawa S; Nagasaka K; Nakagawa K; Minaguchi T; Wada O; Ooishi H; Matsumoto K; Yasugi T; Kanda T; Huibregtse JM; Taketani Y
J Med Virol; 2006 Apr; 78(4):501-7. PubMed ID: 16482544
[TBL] [Abstract][Full Text] [Related]
3. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.
Park JS; Kim EJ; Lee JY; Sin HS; Namkoong SE; Um SJ
Int J Cancer; 2001 Mar; 91(6):822-7. PubMed ID: 11275986
[TBL] [Abstract][Full Text] [Related]
4. Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
Stutz C; Reinz E; Honegger A; Bulkescher J; Schweizer J; Zanier K; Travé G; Lohrey C; Hoppe-Seyler K; Hoppe-Seyler F
PLoS One; 2015; 10(7):e0132339. PubMed ID: 26151636
[TBL] [Abstract][Full Text] [Related]
5. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
Mansur CP; Marcus B; Dalal S; Androphy EJ
Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
[TBL] [Abstract][Full Text] [Related]
6. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function.
Cherry JJ; Rietz A; Malinkevich A; Liu Y; Xie M; Bartolowits M; Davisson VJ; Baleja JD; Androphy EJ
PLoS One; 2013; 8(12):e84506. PubMed ID: 24376816
[TBL] [Abstract][Full Text] [Related]
7. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
8. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells.
Munagala R; Kausar H; Munjal C; Gupta RC
Carcinogenesis; 2011 Nov; 32(11):1697-705. PubMed ID: 21859835
[TBL] [Abstract][Full Text] [Related]
9. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein.
Beerheide W; Bernard HU; Tan YJ; Ganesan A; Rice WG; Ting AE
J Natl Cancer Inst; 1999 Jul; 91(14):1211-20. PubMed ID: 10413422
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation.
Cheng YW; Wu MF; Wang J; Yeh KT; Goan YG; Chiou HL; Chen CY; Lee H
Cancer Res; 2007 Nov; 67(22):10686-93. PubMed ID: 18006810
[TBL] [Abstract][Full Text] [Related]
11. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.
Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL
Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435
[TBL] [Abstract][Full Text] [Related]
12. Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
Conrady MC; Suarez I; Gogl G; Frecot DI; Bonhoure A; Kostmann C; Cousido-Siah A; Mitschler A; Lim J; Masson M; Iftner T; Stubenrauch F; Travé G; Simon C
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115863
[TBL] [Abstract][Full Text] [Related]
13. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
[TBL] [Abstract][Full Text] [Related]
14. Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein.
Zhang Y; Dasgupta J; Ma RZ; Banks L; Thomas M; Chen XS
J Virol; 2007 Apr; 81(7):3618-26. PubMed ID: 17267502
[TBL] [Abstract][Full Text] [Related]
15. Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6.
Wang H; Mo P; Ren S; Yan C
J Biol Chem; 2010 Apr; 285(17):13201-10. PubMed ID: 20167600
[TBL] [Abstract][Full Text] [Related]
16. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting.
Griffin H; Elston R; Jackson D; Ansell K; Coleman M; Winter G; Doorbar J
J Mol Biol; 2006 Jan; 355(3):360-78. PubMed ID: 16324714
[TBL] [Abstract][Full Text] [Related]
19. Degradation of p53 by natural variants of the E6 protein of human papillomavirus type 16.
Yi JW; Jang M; Kim SJ; Kim SS; Rhee JE
Oncol Rep; 2013 Apr; 29(4):1617-22. PubMed ID: 23404471
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex.
Gewin L; Myers H; Kiyono T; Galloway DA
Genes Dev; 2004 Sep; 18(18):2269-82. PubMed ID: 15371341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
